The antitumor activity of MET inhibitor crizotinib and pan-class I PI3K inhibitor BKM120 alone or in combination was further investigated in a mouse PDX mesothelioma model (conducted by Champions Oncology, Baltimore, MD). The gene discussed is MET; the disease is mesothelioma.